Literature DB >> 29634060

Synthesis, characterization, and cytotoxic properties of mono- and di-nuclear cobalt(ii)-polypyridyl complexes.

Arvin Eskandari1, Arunangshu Kundu, Chunxin Lu, Sushobhan Ghosh, Kogularamanan Suntharalingam.   

Abstract

We report the synthesis and characterisation of mono- and di-nuclear cobalt(ii) complexes (1-3) containing L1, a polypyridyl ligand with pyrazole moieties. DNA binding studies suggest that the mono-nuclear complex, 1, binds to DNA via the grooves prior to inducing oxidative DNA cleavage whereas the larger di-nuclear complexes, 2 and 3, bind to DNA via the grooves and through intercalation prior to inducing oxidative DNA cleavage. The cobalt(ii) complexes display micromolar potency towards U2OS (bone osteosarcoma), HepG2 (liver hepatocellular carcinoma), and GM05757 (normal human fibroblast) cells, comparable to clinically used platinum agents, cisplatin and carboplatin. The cellular mechanism of action studies show that the most effective cobalt(ii) complex, 2, enters U2OS cells, penetrates the nucleus, induces genomic DNA damage, and triggers caspase-dependent apoptosis in a p53-independent manner. This study highlights the potential of di-nuclear cobalt(ii) complexes as artificial oxidative metallonucleases and tangible cancer cell-potent agents.

Entities:  

Year:  2018        PMID: 29634060     DOI: 10.1039/c8dt00577j

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  2 in total

1.  Antiproliferative, DNA binding, and cleavage properties of dinuclear Co(III) complexes containing the bioactive quinizarin ligand.

Authors:  Hana Crlikova; Hana Kostrhunova; Jitka Pracharova; Máté Kozsup; Sándor Nagy; Péter Buglyó; Viktor Brabec; Jana Kasparkova
Journal:  J Biol Inorg Chem       Date:  2020-02-28       Impact factor: 3.358

2.  A dual-targeting ruthenium nanodrug that inhibits primary tumor growth and lung metastasis via the PARP/ATM pathway.

Authors:  Yu Lu; Di Zhu; Lin Gui; Yuanming Li; Wenjing Wang; Jiawang Liu; Yuji Wang
Journal:  J Nanobiotechnology       Date:  2021-04-23       Impact factor: 10.435

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.